Catalyst
Slingshot members are tracking this event:
Mallinckrodt (MNK) to complete Phase 3 Study of Baclofen Injection (Intrathecal) in patients with severe spasticity in October 2016
- Source Link:
- https://clinicaltrials.gov/ct2/show/NCT01520545
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MNK |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 18, 2016
Occurred Source:
https://clinicaltrials.gov/archive/NCT01520545/2016_10_18/changes
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Gablofen, Baclofen, Intrathecal Administration, Severe Spasticity, Phase 3 Study, Single Group, Open-label
